Inactivation of Extended-spectrum β-lactamase (ESBL)-producing Escherichia coli by UVA-LED irradiation system

J Med Invest. 2020;67(1.2):163-169. doi: 10.2152/jmi.67.163.

Abstract

The prevalence of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli is increasing rapidly and spreading worldwide, particularly in Asia, compared to other regions. In the last ten years, in our hospital, in particular, there has been a < 30% increase. To prevent the spread of ESBL in hospitals and the community, the ultraviolet (UV) A-light-emitting diode (LED) irradiation device was used to inactivate ESBL-E. coli in human livestock and the environment. ESBL-E. coli and E. coli bacterial samples were collected from patients at Tokushima University Hospital (Tokushima City, Japan). The UVA-LED irradiation system had 365 nm single wavelength, and the current of the circuit was set to 0.23 or 0.50 A consistently. Results demonstrated that UVA-LED was useful for the inactivation of ESBL-E. coli and E. coli. The minimum energy dosage required to inactivate ESBL-E. coli and E. coli was 40.76 J/cm2 (45 min) in the first type of UVA-LED and 38.85 J/cm2 (5 min) in the second type. There were no significant differences between ESBL-E. coli and E. coli. The inactivation of ESBL-E. coli was dependent on energy. These findings suggest that UVA-LED with 365 nm single wavelength could be useful for surface decontamination in healthcare facilities. J. Med. Invest. 67 : 163-169, February, 2020.

Keywords: E. coli; ESBL-E; UVA-LED irradiation; coli; extended-spectrum β-lactamase (ESBL).

MeSH terms

  • Decontamination / methods*
  • Escherichia coli / enzymology
  • Escherichia coli / radiation effects*
  • Health Facilities
  • Ultraviolet Rays*
  • beta-Lactamases / biosynthesis*

Substances

  • beta-Lactamases